prenoxadinjection.com Report : Visit Site

Technical data of the prenoxadinjection.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host prenoxadinjection.com. Currently, hosted in United Kingdom and its service provider is Digital Continuity Limited .

martindalepharma.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

device height maximum-scale = 1.0 retains dimensions instead of zooming in if page width -- -- -- -- -- prenoxad ® injection click here if you are a healthcare professional click here if you work in drug and alcohol treatment services click here if you or someone you represent has been prescribed click here if you are a healthcare professional click here if you work in drug and alcohol treatment services click here if you or someone you represent has been prescribed -- click here if you are a healthcare professional click here if you work in drug and alcohol treatment services click here if you or someone you represent has been prescribed -- © copyrights . 2013 prescribing information | privacy policy prescribing information for prenoxad 1mg/ml injection please refer to summary of product characteristics before prescribing. presentation: a 2ml pre-filled syringe containing naloxone hydrochloride 1mg/ml. indications: is intended for emergency use in the home or other non-medical setting by appropriate individuals or in a health facility setting for the complete or partial reversal of respiratory depression induced by natural and synthetic opioids, including methadone, diamorphine (dicetylemorphine (inn)) and certain other opioids such as dextropropoxyphene and certain mixed agonist/antagonist analgesics: nalbuphine and pentazocine. should be carried by persons at risk of such events. it may also be used for the diagnosis of suspected acute opioid overdose. dosage and administration: : may only be made available once the prescriber has assessed the suitability and competence of a client or representative to administer naloxone in the appropriate circumstances. is for administration by intramuscular injection. adults and the elderly: opioid overdosage (known or suspected). for use by individuals in the community. in patients where breathing does not appear to be normal. in patients where breathing does not appear to be normal administration of should be preceded by calling emergency services and requesting an ambulance. following this, 30 chest compressions and if possible 2 rescue breaths (basic life support single cycle) should be given; 0.4ml solution should then be administered by intramuscular injection into the outer thigh muscle or muscles of the upper arm, through clothing if necessary. a further 3 cycles of chest compressions and rescue breaths should then be given followed by administration of 0.4ml . three cycles of chest compression and rescue breaths should take approximately 2 minutes. this should be repeated until an ambulance arrives or the patient begins breathing normally / regains consciousness. the patient when breathing normally or has regained consciousness should be placed in the recovery position (lying on their side, mouth open pointing towards the ground) and observed continuously. in patients were breathing is normal but the patient is unrousable or suspected to be unconscious. the patient should be placed in the recovery position. 0.4ml solution should be administered by intramuscular injection into the outer thigh muscle or muscles of the upper arm, through clothing if necessary, and an ambulance should be called. 0.4ml solution should then be administered every 2-3 minutes and continued until the ambulance arrives and or the patient regains consciousness. children and neonates: the presentation is not intended to be used for children in the home setting other than by an appropriately trained healthcare professional. contra-indications: known hypersensitivity to naloxone or any of the ingredients. warnings and precautions: is intended as an emergency treatment and the patient should be advised to seek medical help immediately.it should be administered cautiously to patients who have received large doses of opioids or to those physically dependent on opioids since too rapid reversal of opioid effects by prenoxad may precipitate an acute withdrawal syndrome in such patients. patients who have responded satisfactorily to prenoxad should be kept under medical observation for at least 2 hours. repeated doses of prenoxad may be necessary since the duration of action of some opioids may exceed that of prenoxad. use with caution in patients with pre-existing cardiac, hepatic or renal disease and in those receiving medications with potential adverse cardiovascular effects e.g. hypotension, ventricular tachycardia or fibrillation and pulmonary oedema. caution should be exercised and patients monitored when is administered to this patients with renal insufficiency/failure or liver disease. interactions: administer cautiously to opioid dependent patients including newborns of mother’s dependant or those suspected of having received large doses and observe for signs of acute withdrawal. pregnancy and lactation: prenoxad should be used with caution in pregnancy. the neonate must also be monitored for signs of opioid withdrawal. naloxone may be administered during the second stage of labour to correct any respiratory depression due opioid analgesics. it is not known whether naloxone is excreted in human milk therefore use with caution in breastfeeding mothers. undesirable effects: common side effects include nausea, vomiting, dizziness, headache, ventricular tachycardia, hypotension and hypertension. less common side effects: tremor, sweating, arrhythmia, bradycardia, diarrhoea, dry mouth, hyperventilation, inflammation. seizure tension, allergic recations, anaphylactic shock, fibrillation, cardiac arrest, erythema multiforme, fever, dyspnoea, runny nose, sneezing and yawning. piloerection, weakness, shivering. product licence number: pl 12064/0125 product licence holder: aurum pharmaceuticals ltd, bampton road, harold hill, romford, essex rm3 8ug basic nhs price: £18.00 legal category: pom. date of preparation: april 2013 for more details contact: aurum pharmaceuticals ubert road, brentwood, essex cm14 4lz 01277 266600 adverse events should be reported. reporting forms and information can be found at www.mhra.gov.uk/yellowcard. adverse events should also be reported to martindale pharma tel. 01277 266600 fax 01708 382739 e-mail [email protected] privacy policy electronic personal information privacy policy (“privacy policy”) martindale pharma (“we”) are committed to protecting and respecting your privacy. this privacy policy is designed to tell you about our practices regarding collection, use, and disclosure of personally identifiable information that you may provide us, or that we may collect from you, which is then processed by us. . please be sure to read this entire privacy policy before using, or submitting information, to www.martindalepharma.co.uk (“this site”). this site is governed by english law. use of this site constitutes your consent to the application of such laws and to this privacy policy. for the purposes of the data protection act 1998, the data controller is macarthys laboratories limited trading as “martindale pharma”. active information collection this site may actively collect and process information from you by asking you specific questions; and by permitting you to communicate directly with us via e-mail, employment applications, surveys and/or feedback forms. some of the information that you submit may be personally identifiable information (e.g., e-mail address). please note that we may ask you for information when you report a problem with this site. further, some areas of this site may require you to submit information in order for you to benefit from the specified features (e.g., newsletters, employment applications) or to participate in a particular activity (e.g., promotions). you will be informed in each instance what information is required, the purpose for which it is collected and what information is optional. passive information collection as you navigate through a web site, certain information can be passively collected using various technologies and means including internet protoco

URL analysis for prenoxadinjection.com

http://www.prenoxadinjection.com/hcp/abt_naloxone.html
http://www.prenoxadinjection.com/ru/
http://www.prenoxadinjection.com/medical/abt_naloxone.html
http://www.prenoxadinjection.com/../index.html
http://www.prenoxadinjection.com/drug/use_naloxone.html
ico.gov.uk
mhra.gov.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: PRENOXADINJECTION.COM
Registry Domain ID: 1794991077_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.meshdigital.com
Registrar URL: http://www.domainbox.com
Updated Date: 2017-04-12T00:00:00Z
Creation Date: 2013-04-19T00:00:00Z
Registrar Registration Expiration Date: 2018-04-19T00:00:00Z
Registrar: WEBFUSION LIMITED
Registrar IANA ID: 1515
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.8779770099
Reseller: 123Reg/Webfusion
Domain Status: ok
Registry Registrant ID:
Registrant Name: Macarthys Laboratories Limited trading as Martindale Pharma
Registrant Organization: Macarthys Laboratories Limited trading as Martindale Pharma
Registrant Street: Hubert Road
Registrant City: Brentwood
Registrant State/Province: Brentwood
Registrant Postal Code: CM14 4JY
Registrant Country: GB
Registrant Phone: +44.1277266600
Registrant Phone Ext:
Registrant Fax Ext:
Registrant Email: [email protected]
Registry Admin ID:
Admin Name: Macarthys Laboratories Limited trading as Martindale Pharma
Admin Organization: Macarthys Laboratories Limited trading as Martindale Pharma
Admin Street: Hubert Road
Admin City: Brentwood
Admin State/Province: Brentwood
Admin Postal Code: CM14 4JY
Admin Country: GB
Admin Phone: +44.1277266600
Admin Phone Ext:
Admin Fax Ext:
Admin Email: [email protected]
Registry Tech ID:
Tech Name: Macarthys Laboratories Limited trading as Martindale Pharma
Tech Organization: Macarthys Laboratories Limited trading as Martindale Pharma
Tech Street: Hubert Road
Tech City: Brentwood
Tech State/Province: Brentwood
Tech Postal Code: CM14 4JY
Tech Country: GB
Tech Phone: +44.1277266600
Tech Phone Ext:
Tech Fax Ext:
Tech Email: [email protected]
Name Server: ns.123-reg.co.uk
Name Server: ns2.123-reg.co.uk
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-07-19T22:42:53Z <<<

For more information on Whois status codes, please visit https://icann.org/epp


The Data in this WHOIS database is provided
for information purposes only, and is designed to assist persons in
obtaining information related to domain name registration records.
It's accuracy is not guaranteed. By submitting a
WHOIS query, you agree that you will use this Data only for lawful
purposes and that, under no circumstances will you use this Data to:
(1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail(spam);
or (2) enable high volume, automated, electronic processes that
apply to this WHOIS or any of its related systems. The provider of
this WHOIS reserves the right to modify these terms at any time.
By submitting this query, you agree to abide by this policy.

LACK OF A DOMAIN RECORD IN THE WHOIS DATABASE DOES
NOT INDICATE DOMAIN AVAILABILITY.

  REGISTRAR 123-REG LIMITED

  REFERRER http://www.meshdigital.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =prenoxadinjection.com

  PORT 43

  SERVER whois.123-reg.co.uk

  ARGS prenoxadinjection.com

  PORT 43

  TYPE domain

DOMAIN

  NAME prenoxadinjection.com

NSERVER

  NS.123-REG.CO.UK 212.67.202.2

  NS2.123-REG.CO.UK 62.138.132.21

STATUS
ok https://icann.org/epp#ok

  CHANGED 2017-04-12

  CREATED 2013-04-19

  EXPIRES 2018-04-19

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .